An Expanding Life. First TAVI System CE Approved for Intermediate Risk Patients.
Life is different for TAVI patients who benefit from a supra-annular, self-expanding valve.
COREVALVE™ EVOLUT™ R Tavi System
The unique design of the CoreValve Evolut R TAVI system delivers procedural safety and excellent valve performance important for the treatment of intermediate risk patients.
Notion Trial 2-Year Outcomes
Data from the NOTION trial demonstrated that comparable clinical outcomes to surgical AVR can be achieved by using the CoreValve Evolut R system in patients who are intermediate risk surgical candidates.VIEW NOTION TRIAL ABSTRACT
Designed for and
Consistent performance in pivotal trials and real-world results.
Control During Deployment
First time positioning accuracy with the ability to recapture and reposition the valve.
Excellent Valve Performance
Supra-annular design provides excellent and stable hemodynamic performance.
Designed for Durability
Clinical data demonstrating sustained valve performance out to 5 years.1
Barbanti, et al., J Am Coll Cariol Intv 2015; 8: 1084-91.
INTERNATIONAL CAUTION: For distribution only in markets where CoreValve Evolut R intermediate risk indication has been approved. Not for distribution in the U.S. Refer to Instructions for Use for a complete list of warnings, precautions, indications and contraindications.
UC201701719 EE 08/2016
©2016 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.